Article

A third COVID-19 vaccine shot markedly boosts neutralizing antibody potency and breadth

2021-08-18

Abstract excerpt

COVID-19 (coronavirus disease 2019) vaccines have been rapidly developed and deployed globally as a measure to combat the disease. These vaccines have been demonstrated to confer significant protection, but there have been reports of temporal decay in antibody titer. Furthermore, several variants have been identified with variable degrees of antibody resistance. These two factors suggest that a booster vaccination...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 52576911-737f-52ef-a390-4d343f7d0b8d
DOI: 10.1101/2021.08.11.21261670

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A third COVID-19 vaccine shot markedly boosts neutralizing antibody potency and breadthDOI 10.1101/2021.08.11.21261670Read

Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccinesSemantic proximity Read

Increased seroprevalence and improved antibody responses following third primary SARS-CoV-2 immunisation: an update from the COV-AD studySemantic proximity Read

Naturally enhanced neutralizing breadth to SARS-CoV-2 after one yearSemantic proximity Read

Immunogenicity and safety of the homogenous booster shot of a recombinant fusion protein vaccine (V-01) against COVID-19 in healthy adult participants primed with a two-dose regimenSemantic proximity Read

Determinants of Antibody Responses to Two Doses of ChAdOx1 nCoV-19 or Bnt162b2 and a Subsequent Booster Dose of BNT162b2 or mRNA-1273: Population-Based Cohort Study (COVIDENCE UK)Semantic proximity Read

Determinants of antibody responses to two doses of ChAdOx1 nCoV-19 or BNT162b2 and a subsequent booster dose of BNT162b2 or mRNA-1273: population-based cohort study (COVIDENCE UK)Semantic proximity Read

A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2Semantic proximity Read

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19Semantic proximity Read

Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccineSemantic proximity Read

Previously infected vaccinees broadly neutralize SARS-CoV-2 variantsSemantic proximity Read

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1Semantic proximity Read

XBB .1.5 neutralizing antibodies upon bivalent COVID ‐19 vaccination are similar to XBB but lower than BQ .1.1Semantic proximity Read